These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 6125207)

  • 1. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS; Silas JH; Freestone S; Trevethick J
    Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS; Tucker GT; Silas JH; Woods HF
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
    Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
    Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.
    al-Hadidi HF; Irshaid YM; Rawashdeh NM
    Eur J Clin Pharmacol; 1994; 47(4):311-4. PubMed ID: 7875180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation phenotype--a major determinant of metoprolol metabolism and response.
    Lennard MS; Silas JH; Freestone S; Ramsay LE; Tucker GT; Woods HF
    N Engl J Med; 1982 Dec; 307(25):1558-60. PubMed ID: 7144837
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
    Lewis RV; Ramsay LE; Jackson PR; Yeo WW; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1991 Apr; 31(4):391-8. PubMed ID: 2049246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic metabolism of metoprolol: clinical studies.
    Silas JH; McGourty JC; Lennard MS; Tucker GT; Woods HF
    Eur J Clin Pharmacol; 1985; 28 Suppl():85-8. PubMed ID: 4054194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.
    Freestone S; Silas JH; Lennard MS; Ramsay LE
    Br J Clin Pharmacol; 1982 Nov; 14(5):713-8. PubMed ID: 7138751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
    Lennard MS; Tucker GT; Silas JH; Freestone S; Ramsay LE; Woods HF
    Clin Pharmacol Ther; 1983 Dec; 34(6):732-7. PubMed ID: 6641087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS; Jackson PR; Freestone S; Ramsay LE; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.